Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01047527 · ClinicalTrials.gov registry record · Phase 4
An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 525
- Enrollment target
NCT01047527: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01047527 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 525 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01047527, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 525 participants
- Enrollment target
Study Summary
The transdermal nicotine patch is the most widely used form of tobacco dependence treatment in the US and Europe, but most smokers are unable to successfully quit with this form of treatment. Failure to respond to this treatment may, to a large extent, be due to the use of nicotine patches for only 8 weeks, the recommended treatment duration. We have found in a controlled randomized clinical trial that using the nicotine patch for 24 weeks can increase quit rates significantly. We propose here a clinical trial to replicate and extend these results to a community setting in the real-world, using the same research design utilized in clinical trials to demonstrate the effectiveness of methadone maintenance therapy for opiate dependence. Specifically, 540 smokers will receive counseling and standard (8-weeks), extended (24-weeks), or maintenance (52 weeks) therapy with transdermal nicotine patches. The main outcome is biochemically-verified smoking cessation at week 52. The cost-effectiveness, safety, and mechanism of effect (e.g., promotion of recovery following a lapse) for maintenance therapy with transdermal nicotine will also be assessed. The study results may change how we treat nicotine dependence with transdermal nicotine.
Primary Outcome
self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide
Interventions
- DRUG Transdermal nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
What the finished NCT01047527 record still lists
NCT01047527 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Transdermal nicotine patch is the first listed.
NCT01047527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01047527 about?
NCT01047527 is a clinical study titled "An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence". The transdermal nicotine patch is the most widely used form of tobacco dependence treatment in the US and Europe, but most smokers are unable to successfully quit with this form of treatment. Failure to respond to this treatment may, to a large extent, be due to the use of nicotine patches for only ...
What is the current status of trial NCT01047527?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 525 participants. The study started on 2009-06. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01047527?
The interventions under investigation include: Transdermal nicotine patch (DRUG).
Who is sponsoring clinical trial NCT01047527?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01047527's enrollment target sits among peer trials
525 157th of 2000 higher than 1,844 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia